Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

Theodore A. Braich, Sydney E. Salmon, Aurelia Robertone, David S. Alberts, Stephen E. Jones, Thomas P. Miller, Harinder S. Garewal

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.

Original languageEnglish (US)
Pages (from-to)269-274
Number of pages6
JournalInvestigational New Drugs
Volume4
Issue number3
DOIs
StatePublished - Sep 1986

Keywords

  • esorubicin
  • phase II

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma'. Together they form a unique fingerprint.

  • Cite this